May 21, 2025

Sarah Cannon Research Institute Welcomes Hans Lee, MD, as Director of Myeloma Research

Dr. Hans Lee to Lead SCRI Myeloma Research and Practice Locally at SCRI Oncology Partners in Nashville

Nashville, Tenn. {May 21, 2025} – Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, is pleased to announce the appointment of Hans Lee, MD, as Director of Myeloma Research for SCRI. Dr. Lee, globally recognized for his expertise, will be instrumental in providing scientific leadership and oversight for SCRI’s comprehensive myeloma clinical trial menu across its vast network of more than 200 locations. In addition to his leadership role at SCRI, Dr. Lee will serve as a medical oncologist at SCRI Oncology Partners, a practice in The US Oncology Network in Nashville, Tenn. starting June 1.

“We are thrilled to have Dr. Lee join us in expanding our myeloma research program and providing greater access to cutting-edge therapies to patients close to home,” said David Spigel, MD, Chief Scientific Officer of SCRI and medical oncologist at SCRI Oncology Partners. “Dr. Lee brings extensive clinical research expertise with a focus on advancing therapies for patients facing myeloma – a type of blood cancer with increasing survival rates as a result of innovations made possible through clinical trials.”

Dr. Lee joins SCRI and SCRI Oncology Partners from The University of Texas MD Anderson Cancer Center in Houston, where he served as the Director of Multiple Myeloma Clinical Research and Associate Professor within the Department of Lymphoma/Myeloma. Dr. Lee received his undergraduate degree from Purdue University and his Doctor of Medicine degree from Indiana University School of Medicine, followed by residency (internal medicine) at Washington University School of Medicine/Barnes-Jewish Hospital. He completed his clinical fellowship (hematology/oncology) at University of Texas MD Anderson Cancer Center, where he was the Chief Hematology Fellow.

Dr. Lee is dual board-certified in hematology and medical oncology and has been actively involved in several professional and scientific committees, including the American Society of Hematology Foundation Committee, National Cancer Institute Clinical Trials Evaluation Program, and the National Comprehensive Cancer Network Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenstrom’s Macroglobulinemia Panel. Dr. Lee’s research has been funded by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and highlighted in 125+ peer-reviewed publications.

About Sarah Cannon Research Institute (SCRI)

About Sarah Cannon Research Institute (SCRI) Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at over 200 locations in more than 20 states across the U.S. Learn more about our research offerings.

Media Contacts

SCRI
Becca Gelman
Becca.Gelman@SCRI.com